MediLink Therapeutics, a clinical-stage biotech company, announced today that its internally developed antibody-drug conjugate (ADC), YL217, has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA). YL217 is the 11th ADC candidate to enter clinical development based on MediLink’s proprietary TMALIN® platform.
YL217: A Novel ADC Targeting Gastrointestinal Cancers
YL217 is an innovative ADC targeting a novel antigen highly expressed in gastrointestinal tumors, including gastric, colorectal, pancreatic, and hepatocellular cancers. The target is associated with the metastatic progression of gastrointestinal-origin malignancies and is upregulated in advanced, well-differentiated tumors. Developed using MediLink’s next-generation tumor microenvironment-activatable linker technology (TMALIN®), YL217 is poised to enter Phase I clinical trials.
MediLink Therapeutics: Pioneering Next-Gen ADC Platforms
Founded in 2020, MediLink Therapeutics is a clinical-stage biotech company dedicated to developing innovative conjugate therapies. The company has established a robust pipeline of proprietary linker technologies, including its TMALIN® platform, which utilizes camptothecin-based payloads activated in the tumor microenvironment. To date, ten ADC candidates based on TMALIN® have received clinical approval in both the U.S. and China. Headquartered in Suzhou with offices in Boston, Shanghai, and Singapore, MediLink is committed to addressing unmet medical needs and delivering transformative therapies for cancer patients worldwide.-Fineline Info & Tech
Leave a Reply